Skip to content

Study · Randomized controlled trial · n = 109 · 2002

3 results

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.

Ruether E, Alvarez XA, Rainer M, Moessler H

Journal of neural transmission. Supplementum1 Jan 2002Cited by 14 (Europe PMC)

PMID12456069 (opens in a new tab)DOI10.1007/978-3-7091-6139-5_24 (opens in a new tab)PepBankPUB-12456069
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Alzheimer's disease patients with MMSE scores <20, CGI response was 65% with Cerebrolysin versus 24.5% with placebo.

    In plain wordsIn Alzheimer's disease patients, global response was 65% with Cerebrolysin versus 24.5% with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCGI responder rate
    Study

    n = 109

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · infusion · four weeks, repeated after a two-months therapy-free intervalAs given in this study (human).

    Measurements

    CGI responder rate
    65%
    Cere
    CGI responder rate
    24.5%
    placebo
    P value for CGI responder rate comparison
    < 0.004
    Cere versus placebo in patients with MMSE scores <20

    Source sentences

    Summary
    The responder rate of the Cere group was 65% on the CGI, compared to 24.5% in the placebo group (p < 0.004).
    4 context sentences
    Summary · context
    A subgroup analysis of this double-blind, placebo-controlled study was performed to assess the effects of Cere in cases with more advanced forms of AD.
    Summary · context
    Patients received infusions of 30 ml Cere or placebo five days/week for four weeks.
    Summary · context
    This treatment was repeated after a two-months therapy-free interval.
    Summary · context
    109 patients with MMSE scores <20 were included in this analysis.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Alzheimer's disease patients with MMSE scores <20, ADAS-cog favored Cerebrolysin over placebo by 4.1 points.

    In plain wordsIn Alzheimer's disease patients, thinking scores favored Cerebrolysin over placebo by 4.1 points.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseADAS-cog score
    Study

    n = 109

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · infusion · four weeks, repeated after a two-months therapy-free intervalAs given in this study (human).

    Measurements

    ADAS-cog score difference
    4.1 points
    in favour of Cere
    P value for ADAS-cog score difference
    < 0.0001
    Cere versus placebo in patients with MMSE scores <20

    Source sentences

    Summary
    In the ADAS-cog, a score difference of 4.1 points in favour of Cere was observed (p < 0.0001).
    4 context sentences
    Summary · context
    A subgroup analysis of this double-blind, placebo-controlled study was performed to assess the effects of Cere in cases with more advanced forms of AD.
    Summary · context
    Patients received infusions of 30 ml Cere or placebo five days/week for four weeks.
    Summary · context
    This treatment was repeated after a two-months therapy-free interval.
    Summary · context
    109 patients with MMSE scores <20 were included in this analysis.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Alzheimer's disease patients, improvements with Cerebrolysin were largely maintained through week 28.

    In plain wordsIn Alzheimer's disease patients, improvements after Cerebrolysin were largely maintained through week 28.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMaintenance of improvements
    Study

    n = 109

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · infusion · four weeks, repeated after a two-months therapy-free intervalAs given in this study (human).

    Source sentences

    Summary
    Notably, improvements were largely maintained in the Cere group up to the week 28 visit.
    4 context sentences
    Summary · context
    A subgroup analysis of this double-blind, placebo-controlled study was performed to assess the effects of Cere in cases with more advanced forms of AD.
    Summary · context
    Patients received infusions of 30 ml Cere or placebo five days/week for four weeks.
    Summary · context
    This treatment was repeated after a two-months therapy-free interval.
    Summary · context
    109 patients with MMSE scores <20 were included in this analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.